JW Pharmaceutical Corporation

Symbol: 001067.KS

KSC

57400

KRW

Market price today

  • 36.6572

    P/E Ratio

  • 0.9260

    PEG Ratio

  • 684.88B

    MRK Cap

  • 0.01%

    DIV Yield

JW Pharmaceutical Corporation (001067-KS) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.45%

Operating Profit Margin

0.13%

Net Profit Margin

0.05%

Return on Assets

0.06%

Return on Equity

0.14%

Return on Capital Employed

0.28%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Young-Sub Shin
Full-time employees:1197
City:Seoul
Address:2477, Nambusunhwan-ro
IPO:2005-09-29
CIK:

JW Pharmaceutical Corporation develops, manufactures, and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cardiovascular, gastrointestinal, urinary, oral hypoglycemic, antibiotics, anti-fungal, Ob and Gy, renal, CNS, anti-anemic, respiratory, rheumatic arthritis, anticancer, anesthetic, antidotes, amino acids, TPN, and others. The company was founded in 1945 and is headquartered in Seoul, South Korea.

General Outlook

When we look at how much money they make before expenses, they keep 0.448% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.134%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.049%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.057% return, is a testament to JW Pharmaceutical Corporation's adeptness in optimizing resource deployment. JW Pharmaceutical Corporation's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.145%. Furthermore, the proficiency of JW Pharmaceutical Corporation in capital utilization is underscored by a remarkable 0.279% return on capital employed.

Liquidity Ratios

Analyzing 001067.KS liquidity ratios reveals its financial health of the firm. The current ratio of 131.77% gauges short-term asset coverage for liabilities. The quick ratio (92.87%) assesses immediate liquidity, while the cash ratio (5.54%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio131.77%
Quick Ratio92.87%
Cash Ratio5.54%

Profitability Ratios

001067.KS profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 7.26% underscores its earnings before tax deductions. The effective tax rate stands at 30.21%, revealing its tax efficiency. The net income per EBT, 68.14%, and the EBT per EBIT, 54.33%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 13.35%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin7.26%
Effective Tax Rate30.21%
Net Income per EBT68.14%
EBT per EBIT54.33%
EBIT per Revenue13.35%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.32, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding93
Days of Inventory Outstanding94
Operating Cycle178.43
Days of Payables Outstanding65
Cash Conversion Cycle113
Receivables Turnover4.31
Payables Turnover5.59
Inventory Turnover3.89
Fixed Asset Turnover4.81
Asset Turnover1.16

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 3809.98, and free cash flow per share, 2124.29, depict cash generation on a per-share basis. The cash per share value, 4058.31, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.12, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share3809.98
Free Cash Flow per Share2124.29
Cash per Share4058.31
Operating Cash Flow Sales Ratio0.12
Free Cash Flow to Operating Cash Flow Ratio0.56
Cash Flow Coverage Ratio0.59
Short Term Coverage Ratio0.74
Capital Expenditure Coverage Ratio2.26
Dividend Paid and Capex Coverage Ratio2.26
Dividend Payout Ratio0.01

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 22.85%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.56, we discern the balance between debt and equity financing. The long-term debt to capitalization, 10.15%, and total debt to capitalization, 35.70%, ratios shed light on its capital structure. An interest coverage of 10.39 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio22.85%
Debt Equity Ratio0.56
Long Term Debt to Capitalization10.15%
Total Debt to Capitalization35.70%
Interest Coverage10.39
Cash Flow to Debt Ratio0.59
Company Equity Multiplier2.43

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 32075.28, provides a glimpse into top-line earnings distributed across each share. Net income per share, 1585.77, reflects the portion of profit attributed to each share. The book value per share, 11374.45, represents the net asset value distributed per share, while the tangible book value per share, 10073.64, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share32075.28
Net Income Per Share1585.77
Book Value Per Share11374.45
Tangible Book Value Per Share10073.64
Shareholders Equity Per Share11374.45
Interest Debt Per Share6854.75
Capex Per Share-1841.20

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 9.38%, indicates top-line expansion, while the gross profit growth, 16.57%, reveals profitability trends. EBIT growth, 53.68%, and operating income growth, 53.68%, offer insights into operational profitability progression. The net income growth, 16.04%, showcases bottom-line expansion, and the EPS growth, 18.69%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth9.38%
Gross Profit Growth16.57%
EBIT Growth53.68%
Operating Income Growth53.68%
Net Income Growth16.04%
EPS Growth18.69%
EPS Diluted Growth18.69%
Weighted Average Shares Growth-2.45%
Weighted Average Shares Diluted Growth-2.45%
Dividends per Share Growth22.89%
Operating Cash Flow Growth53.54%
Free Cash Flow Growth-0.50%
10-Year Revenue Growth per Share40.90%
5-Year Revenue Growth per Share61.15%
3-Year Revenue Growth per Share36.08%
10-Year Operating CF Growth per Share245.38%
5-Year Operating CF Growth per Share93.43%
3-Year Operating CF Growth per Share37.54%
10-Year Net Income Growth per Share1107.04%
5-Year Net Income Growth per Share431.19%
3-Year Net Income Growth per Share341.05%
10-Year Shareholders Equity Growth per Share-1.88%
5-Year Shareholders Equity Growth per Share18.02%
3-Year Shareholders Equity Growth per Share27.29%
10-Year Dividend per Share Growth per Share351.15%
3-Year Dividend per Share Growth per Share26.11%
Receivables Growth7.08%
Inventory Growth-4.99%
Asset Growth2.72%
Book Value per Share Growth13.21%
Debt Growth-18.74%
R&D Expense Growth-0.19%
SGA Expenses Growth61.94%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 1,605,905,478,961, captures the company's total value, considering both debt and equity. Income quality, 2.48, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.16, gauges operational efficiency, while the research and development to revenue, 4.50%, highlights investment in innovation. The ratio of intangibles to total assets, 4.71%, indicates the value of non-physical assets, and capex to operating cash flow, -49.30%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value1,605,905,478,961
Income Quality2.48
Sales General and Administrative to Revenue0.16
Research and Development to Revenue4.50%
Intangibles to Total Assets4.71%
Capex to Operating Cash Flow-49.30%
Capex to Revenue-5.74%
Capex to Depreciation-191.44%
Graham Number20145.41
Return on Tangible Assets6.02%
Graham Net Net-4434.79
Working Capital91,164,236,688
Tangible Asset Value235,084,032,801
Net Current Asset Value-1,506,988,918
Invested Capital1
Average Receivables167,887,746,182.5
Average Payables78,377,546,500
Average Inventory108,879,890,634
Days Sales Outstanding85
Days Payables Outstanding65
Days of Inventory On Hand94
ROIC16.35%
ROE0.14%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 5.11, and the price to book ratio, 5.11, reflect the market's valuation relative to the company's book value. The price to sales ratio, 0.95, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 14.56, and price to operating cash flows, 15.56, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio5.11
Price to Book Ratio5.11
Price to Sales Ratio0.95
Price Cash Flow Ratio15.56
Price Earnings to Growth Ratio0.93
Enterprise Value Multiple1.98
Price Fair Value5.11
Price to Operating Cash Flow Ratio15.56
Price to Free Cash Flows Ratio14.56
Price to Tangible Book Ratio5.47
Enterprise Value to Sales2.15
Enterprise Value Over EBITDA13.47
EV to Operating Cash Flow18.43
Earnings Yield2.55%
Free Cash Flow Yield3.04%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of JW Pharmaceutical Corporation (001067.KS) on the KSC in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 36.657 in 2024.

What is the ticker symbol of JW Pharmaceutical Corporation stock?

The ticker symbol of JW Pharmaceutical Corporation stock is 001067.KS.

What is company IPO date?

IPO date of JW Pharmaceutical Corporation is 2005-09-29.

What is company current share price?

Current share price is 57400.000 KRW.

What is stock market cap today?

The market cap of stock today is 684881761200.000.

What is PEG ratio in 2024?

The current 0.926 is 0.926 in 2024.

What is the number of employees in 2024?

In 2024 the company has 1197.